Indoco Remedies Limited has announced an earnings conference call to discuss its Q3FY26 unaudited financial results. The pharmaceutical company informed both National Stock Exchange of India Limited and Bombay Stock Exchange Limited about the scheduled call through a regulatory filing dated January 20, 2026.

Conference Call Details

The earnings conference call is scheduled to take place on Tuesday, February 3, 2026, at 3:30 PM IST. The call will focus on discussing the company's unaudited financial results for the quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature key members of Indoco Remedies' senior management team who will present the financial results and address investor queries.

Access Information

Nirmal Bang Institutional Equities is hosting the conference call and has provided multiple access options for participants. The call offers both domestic and international dial-in numbers, along with an Express Join feature through DiamondPass for immediate access without waiting time.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Head Legal Ramanathan Hariharan signed the regulatory filing, ensuring compliance with stock exchange notification requirements.

The conference call represents Indoco Remedies' commitment to maintaining transparent communication with investors and stakeholders regarding its financial performance for the third quarter of fiscal year 2026.

Indoco Remedies has achieved a significant regulatory milestone with the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility in Patalganga. The company announced this development through a regulatory filing, following a successful USFDA inspection.

Regulatory Milestone Details

The EIR from USFDA represents successful completion of the regulatory inspection process for the Patalganga facility. This approval confirms that the manufacturing plant meets the stringent quality standards and regulatory requirements mandated by the US health authority.

Strategic Significance

The USFDA EIR approval enhances Indoco Remedies' manufacturing credentials and regulatory standing in the international pharmaceutical market. This certification enables the company to supply APIs manufactured at the Patalganga facility to customers in the United States, one of the world's largest and most lucrative pharmaceutical markets.

The approval demonstrates the company's commitment to maintaining high-quality manufacturing standards and regulatory compliance across its operations. For pharmaceutical companies, USFDA approvals are crucial for accessing the US market and establishing credibility with international customers.

Company Profile

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company operates with a turnover of USD 180.00 million and employs over 6,000 people, including more than 400 skilled scientists and field staff.

This regulatory achievement positions Indoco Remedies favorably for potential business expansion in the US pharmaceutical market and strengthens the company's competitive position in the global API manufacturing sector.